

## KARBINAL ER - (4MG/5ML ; SUSPENSION,EXTENDED RELEASE)

<b>Generic Name</b>	CARBINOXAMINE MALEATE	<b>Innovator</b>	Aytu
<b>Dosage</b>	4MG/5ML ; SUSPENSION,EXTENDED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Karbinal ER (carbinoxamine maleate) extended-release oral suspension is an H1 receptor antagonist indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: • Seasonal and perennial allergic rhinitis • Vasomotor rhinitis • Allergic conjunctivitis due to inhalant allergens and foods • Mild, uncomplicated allergic skin manifestations of urticaria and angioedema • Dermatographism • As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled • Amelioration of the severity of allergic reactions to blood or plasma.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.